Washington Designated Microplastics a Federal Priority Contaminant. Third-Party Suits Won't Wait for the Rule to Follow.

April 08, 2026

WASHINGTON, D.C., On April 2, 2026, the Environmental Protection Agency and the Department of Health and Human Services announced that microplastics and pharmaceuticals would be added to the EPA's Contaminant Candidate List under the Safe Drinking Water Act, marking the first time in the program's history that either category has appeared on the list. EPA Administrator Lee Zeldin and HHS Secretary Robert F. Kennedy Jr. jointly announced the designations, framing them as a coordinated step toward understanding the scale of contamination in the nation's drinking water supply.

The announcement opened a 60-day public comment period, with finalization of the Sixth Contaminant Candidate List expected by November 17, 2026. For water utilities, industrial manufacturers, and municipalities, the designation does not create immediate compliance obligations. What it does create is a formally documented federal acknowledgment that microplastics belong on the regulatory radar, and that acknowledgment carries legal weight well before any enforceable standard takes effect.

What the Contaminant Candidate List Actually Does

The Contaminant Candidate List, known as the CCL, is the formal mechanism under the Safe Drinking Water Act through which EPA identifies substances known or anticipated to appear in public water systems that are not yet subject to a national primary drinking water regulation. The Act requires EPA to publish an updated list every five years and, within five years of finalization, decide whether to regulate at least five of the listed contaminants. The full regulatory process, from listing to enforceable standard, has historically taken two decades or more.

The draft Sixth Contaminant Candidate List includes microplastics and pharmaceuticals as contaminant groups, alongside PFAS, disinfection byproducts, 75 individual chemicals, and nine microbial agents. The inclusion of microplastics is the first of its kind since the CCL program was established. HHS simultaneously announced the Systematic Targeting Of MicroPlastics program (STOMP), a $144 million initiative through the Advanced Research Projects Agency for Health designed to develop tools to measure microplastics in the human body and, in a second phase, remove them.

The Three-Part Liability Exposure

Regulatory Defense Costs

CCL placement does not create an immediate regulatory standard, but it provides a foundation for enforcement by state agencies, local regulators, and plaintiff attorneys who will not wait for federal rulemaking to conclude. Several states, including California and New York, have already begun developing independent microplastics monitoring frameworks. Businesses operating under state-issued permits can face enforcement action, permit modifications, and required monitoring upgrades before any federal rule is finalized. Legal defense costs if enforcement is initiated or a third party brings suit represent a direct and near-term exposure for any facility with documented microplastic discharges.

Third-Party Property Damage and Bodily Injury Claims

Where no regulatory standard exists, plaintiffs have successfully pursued common-law claims, including nuisance, negligence, and trespass, based on documented contamination of drinking water supplies. The CCL designation gives those claims a stronger scientific and legal foundation. Water utilities, plastics manufacturers, and industrial facilities with stormwater discharges that contain microplastics now face a more clearly articulated theory of liability in civil litigation, regardless of where federal rulemaking stands.

Long-Tail Remediation and Litigation Exposure

The STOMP program signals that the federal government intends to build the scientific infrastructure needed to connect microplastic exposure to measurable health outcomes. As standardized measurement methods are developed and validated, the link between contamination sources and individual health impacts will strengthen, creating conditions for large-scale litigation against upstream contributors. The PFAS litigation arc offers a direct precedent: litigation followed by measurability. Facilities in the plastics supply chain, water treatment sector, and industrial manufacturing have every reason to expect the same pattern.

The Coverage Gap

Standard commercial general liability policies contain pollution exclusions that specifically bar coverage for the discharge, dispersal, or migration of pollutants into water supplies. Microplastics, now formally recognized under federal law as contaminants of concern, are positioned to qualify as pollutants under those exclusions. Standard commercial property policies do not address environmental contamination.

Water utilities operating under the Safe Drinking Water Act face an additional complication: monitoring upgrades, infrastructure modifications, and treatment costs triggered by a CCL listing and subsequent regulatory action are unlikely to qualify as covered losses under any standard policy form. The coverage gap is structural, not incidental.

The Coverage Solution

Site Pollution Liability insurance addresses the gap directly. For water utilities, municipalities, plastics manufacturers, and industrial facilities with any connection to microplastic-generating processes, the relevant coverage components include:

The CCL designation does not require immediate action from most businesses. But it means that the next time a plaintiff or regulator needs to establish that microplastics in a water supply represent a recognized environmental concern, the federal government's own contaminant list is Exhibit A. For any business in the plastics supply chain, municipal water sector, or industrial manufacturing, the time to assess Site Pollution Liability coverage is before that argument is made in court, not after.

This article is for informational purposes and does not constitute legal or financial advice.

Sources:

Log In to Share